LRRC37E: A Potential Drug Target in TGF-β Pathway-Related Diseases

Target Name: LRRC37A6P

NCBI ID: G387646

Other Name(s): LRRC37E | Leucine rich repeat containing 37 member A6, pseudogene | leucine rich repeat containing 37 member A6, pseudogene

LRRC37E: A Potential Drug Target in TGF-β Pathway-Related Diseases

LRRC37A6P (LRRC37E) is a protein that is expressed in various tissues of the body, including the brain, heart, kidneys, and intestines. It is a member of the long non-coding RNA (lncRNA) family, which are characterized by the presence of a stem-like region and a polycombination of various functional elements such asmiRNAs, snRNAs, and proteins.

LRRC37E has been shown to play a role in various physiological processes in the body, including cell signaling, metabolism, and inflammation. Its functions have been attributed to its ability to interact with multiple protein partners, including known regulators of cell signaling pathways such as the TGF-β pathway.

Due to its unique structure and the involvement of multiple functional elements, LRRC37E has been identified as a potential drug target in various diseases. One of the primary targets for LRRC37E is the TGF-β pathway, which is a well-established regulator of cell proliferation, differentiation, and survival. The TGF-β pathway has been implicated in a wide range of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

LRRC37E has been shown to play a negative role in the TGF-β pathway by regulating the activity of the transcription factor Smad2. Smad2 is a key regulator of the TGF-β pathway, and its activity is regulated by LRRC37E.

LRRC37E has also been shown to interact with the protein JNK3, which is a known regulator of the TGF-β pathway. The JNK3-LRRC37E interaction has been shown to play a role in the regulation of cellular processes such as cell signaling, stress responses, and inflammation.

In addition to its involvement in the TGF-β pathway, LRRC37E has also been shown to be involved in various other cellular processes, including cell adhesion, migration, and survival. Its functions in these processes have been attributed to its ability to interact with multiple proteins, including the protein ZEB2, which is involved in cell adhesion and migration.

LRRC37E has also been shown to interact with the protein PAX1, which is involved in the regulation of cell signaling pathways. The PAX1-LRRC37E interaction has been shown to play a role in the regulation of cellular processes such as cell signaling, stress responses, and inflammation.

LRRC37E has also been shown to interact with the protein NF-kappa-B, which is a well-established regulator of inflammation and stress responses. The NF-kappa-B-LRRC37E interaction has been shown to play a role in the regulation of cellular processes such as inflammation, stress responses, and cell signaling.

Due to its involvement in multiple cellular processes, LRRC37E has been identified as a potential drug target in various diseases. One of the primary targets for LRRC37E is the TGF-β pathway, which is a well-established regulator of cell proliferation, differentiation, and survival. The TGF-β pathway has been implicated in a wide range of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

LRRC37E has been shown to play a negative role in the TGF-β pathway by regulating the activity of the transcription factor Smad2. Smad2 is a key regulator of the TGF-β pathway, and its activity is regulated by LRRC37E.

LRRC37E has also been shown to interact with the protein JNK3, which is a known regulator of the TGF-β pathway. The JNK3-LRRC37E interaction has been shown to play a role in the regulation of cellular processes such as cell signaling, stress responses, and inflammation.

In addition to its involvement in the TGF-β pathway, LRRC37E has also been shown to be involved in various other cellular processes, including cell adhesion

Protein Name: Leucine Rich Repeat Containing 37 Member A6, Pseudogene

More Common Targets